

Multidisciplinary Treatment In Cardiac Angiosarcoma: Lessons From A Case

J Guimarães, S Sutmöller, M Mano, C Sutmöller, R Venturella, F Franke, A Reiriz, A Notari, A Di Leo

Citation

J Guimarães, S Sutmöller, M Mano, C Sutmöller, R Venturella, F Franke, A Reiriz, A Notari, A Di Leo. *Multidisciplinary Treatment In Cardiac Angiosarcoma: Lessons From A Case*. The Internet Journal of Oncology. 2003 Volume 2 Number 1.

Abstract

A 32 years-old patient with a right atrium angiosarcoma presented with congestive heart failure and chest pain. Primary malignant tumours of the heart are uncommon diseases, typically sarcomas presenting aggressive behaviour and unfavourable prognosis. Due to their rarity, evidence-based recommendations for management are lacking and as a consequence, treatment must be individualised. A multidisciplinary approach is preferred in most cases. Our patient was successfully treated with a sequence of surgery, chemotherapy, and radiotherapy followed by further chemotherapy. A review of the available literature is also provided.

INTRODUCTION

Malignant tumours of the heart and pericardium are rare. The diagnosis may be challenging, due to unspecific symptoms and unpredictable presentation. The prognosis is typically poor and since randomised studies are lacking, therapeutic decisions must be individualised. Treatment is often multidisciplinary, such that the greatest challenge is how to ensure optimal integration of surgery, chemotherapy and radiotherapy. Complete resection is the ultimate goal, although rarely feasible due to anatomic reasons and loco-regional spread. Pre-operative chemotherapy or chemo-radiation may have a role in the management of unresectable tumours.

CASE REPORT

A 32 years-old, previously healthy man presented to the emergency room with fever, atypical chest pain and signs of cardio-respiratory collapse. Unspecific symptoms had started two months before but dramatically worsened a few days prior to presentation. ECG findings were also unspecific. The echocardiography suggested the presence of a cardiac mass, confirmed by transoesophageal echocardiography. A computed tomography (CT scan) showed a large mass extending to the right mediastinum and pericardium, with a moderate pericardial effusion. The superior vena cava was partially compressed (figure 1a). An arteriography was performed and showed signs of neovascularization without evidence of myocardial infarction.

Clinical deterioration prompted thoracotomy, and a tumour mass of 12 cm was found in the right atrium. Resection was incomplete, and the tissue reconstituted with bovine pericardium. Postoperatively, the patient had a cardiac arrest which was successfully reverted. The histological diagnosis was that of a moderately differentiated angiosarcoma, staged IIB according to TNM staging system (G2T2N0M0). The postoperative CT scan showed a significant reduction in the tumour mass such that the patient had no assessable disease prior to the chemo-radiation (figure 1b).

Early post-operative chemotherapy was administered. The regimen consisted in a combination of doxorubicin 20 mg/m²/day, dacarbazine 300 mg/m²/day, and ifosfamide 2500 mg/m²/day with mesna (MAID regimen), given as a continuous infusion for 3 days. Twenty days later the patient received radiotherapy, 54 Gy over 27 days. Chemotherapy was subsequently resumed. A total of 4 cycles were given. At the time of this report, the patient was being followed with regular visits and chest CT scans (every 3-months) and after a follow-up of 12 months, there was no evidence of recurrence.

Figure 1

Figure 1a: preoperative chest CT scan showing a tumour mass in the right atrium





Figure 2

Figure 1b: postoperative chest CT scan: most of the mass was resected



DISCUSSION

Primary tumours of the heart are uncommon diseases, most benign sarcomas, of which 75% are atrial myxomas¹. Among the malignant tumours, angiosarcomas are the most common, followed by non-classifiable sarcomas, malignant fibrous histiocytoma, osteogenic sarcoma, leiomyosarcoma, fibrosarcoma, mixed mesenchymal sarcoma, rhabdomyosarcoma and liposarcoma. The largest series of cardiac angiosarcomas is that of Rettman et al in which they report on 108 cases, confirming their rarity and unfavourable prognosis². Men are twice as commonly affected as women,

typically between the 3rd and 5th decades¹. Their occurrence has also been linked to prolonged immunosuppression in one report³.

Survival in cardiac angiosarcomas is typically of less than 1 year, although it may be much longer in selected cases^{4,5,6}. Aggressive behaviour, as well as delayed diagnosis due to unspecific symptoms, may result in early loco-regional spread. Involvement of mediastinal lymph nodes is frequent. Systemic spread is not uncommon at the time of diagnosis, the lung being the most common site, but metastases have been reported virtually in any organ.

The diagnosis may be a challenging semiotic exercise as patients can present with a multitude of clinical syndromes such as left or right-sided CHF (due either to direct myocardial involvement or to obstruction of venous return as seen with intracavitary tumours), compression of great vessels (sometimes resulting in classical clinical syndromes such as superior vena cava obstruction), ischemic syndromes due to coronary involvement, thromboembolic phenomena^{2,7}, valvular dysfunction⁷, arrhythmia¹ and pericarditis⁷.

Staging should include chest imaging, and magnetic resonance imaging (MRI) appears to produce better vascular imaging, when compared to CT scan⁸. Similarly, transoesophageal echocardiography is superior to transthoracic echocardiography and can also safely guide transvenous biopsy, allowing for pre-operative histological diagnosis⁹. Arteriography (with coronary catheterization) allows for optimal evaluation of peri-tumoral neovascularization as well as the extent of great vessel's involvement and therefore is a crucial step in the surgical planning.

Surgery remains the mainstay of treatment although it is often challenging due to the presence of huge areas of necrosis and extensive loco-regional spread. Pre-operative histological diagnosis and careful evaluation of resectability are recommended. Neo-adjuvant chemotherapy or chemo-radiation may be proposed in patients with unresectable disease. Contrary to earlier reports, encouraging results have been seen with cardiac transplantation in selected patients with localised disease¹. In a series of 15 cardiac sarcomas receiving adjuvant doxorubicin-based chemotherapy regimens, Llombart-Cussac et al reported that 13 eventually presented loco-regional failure, reinforcing the importance of optimal loco-regional therapy⁵. Of interest, one report showed an improved loco-regional control as well as the

feasibility of low doses of radiation with razoxane as a radiosensitizer₆. Although anthracycline-based chemotherapy and cardiac irradiation have both been associated with an increased risk of cardiomyopathy and coronary heart disease, such complications typically occur in the long term such that, considering the poor survival observed in this disease, the potential benefit is likely to outweigh the risk.

Our decision to administer early post-operative chemotherapy in this case was based on young age and incompleteness of surgical resection in the setting of a very aggressive disease. The MAID regimen is known as one of the most active regimens in soft tissue sarcomas₁₀ and has been shown to prolong the time to relapse, although it failed to improve survival and seems more toxic when compared to the combination of doxorubicin and dacarbazine₁₁. In addition, it is unknown whether these results can be extrapolated to angiosarcomas. Liposomal doxorubicin also appears to be active₁₁. One minor response was reported with gemcitabine₁₃, but the most encouraging data come from two phase 2 studies showing the activity of paclitaxel in angiosarcomas of the scalp and face_{14,15}. Combinations of paclitaxel with anthracyclines could further improve response rates and deserve investigation. Responses to immunotherapy with interleukin-2 in angiosarcomas have been reported in sites other than the heart_{16,17}, but not to interferon alpha₁₈. Some authors, however, have questioned the role of early chemotherapy in angiosarcomas based on retrospective, historical comparisons₁₉. Nevertheless, due to their rarity, it is unlikely that this question will ever be answered by controlled trials.

CONCLUSION

The best regimen, duration and timing of chemotherapy remain unknown. The Integration of chemotherapy, radiotherapy and surgery is recommended but the best sequence remains unknown. For the time being, treatment should be individualised. Pre-operative diagnosis and careful surgical planning are crucial. Selected patients with unresectable disease may benefit from neoadjuvant chemotherapy or chemo-radiation.

CORRESPONDENCE TO

Max Mano MD Institut Jules Bordet Rue Héger Bordet 01
1000 Brussels – Belgium Tel: +322 5413476 Fax: +322
5413090 Email: max.mano@bordet.be

References

1. Vander Salm TJ. Unusual primary tumors of the heart. *Semin Thorac Cardiovasc Surg* 2000 Apr ;12(2) :89-100. Review.
2. Rettmair K, Stierle U, Sheikhzadeh A, Diederich KW et al. Primary angiosarcoma of the heart. Report of a case and review of the literature. *Jpn Heart J* 1993 Sep ; 34(5) :667-83.
3. Rigatelli G, Cotogni A, Rugolotto M et al. Extensive cardiac angiosarcoma in the course of immunosuppressive therapy after kidney transplant. *Ital Heart J Sep ; 1(9 Suppl) :1199-202.*
4. Herrmann MA; Shankermans RA; Edward WD et al. Primary cardiac angiosarcoma: a clinicopathologic study of six cases. *J Thorac Cardiovasc Surg* 1992 Apr ; 103(4) :655-64.
5. Llombart-Cussac A, Pivot X, Rhor-Alvarado A et al. Adjuvant chemotherapy for primary cardiac sarcomas : the IGR experience. *Br J Cancer* 1998 Dec ;78(12) :1624-8.
6. Rhombert W, Grass M. Angiosarcoma of the right atrium : local control via low radiation doses and razoxane . A case report. *Strahlenther Onkol* 1999 Mar ;175(3) :102-4.
7. Ananthasubramaniam K, Farha A. Primary right atrial angiosarcoma mimicking acute pericarditis, pulmonary embolism, and tricuspid stenosis. *Heart* 1999 May ;81(5) :556-8.
8. Araoz PA, Eklund HE, Welch TJ, Breen JF. CT and MR imaging of primary cardiac malignancies. *Radiographics* 1999 Nov-Dec ;19(6) :1421-34
9. Hammoudeh AJ; Chaaban F; Watson RM et al. Transesophageal echocardiography-guided transvenous endomyocardial biopsy used to diagnose primary cardiac angiosarcoma. *Cathet Cardiovasc Diagn* 1996 Mar ; 37(3) :347-9.
10. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. *J Clin Oncol*; 7(9):2108-16 1989.
11. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol*; 11(7): 1276-85 1993.
12. Wollina U, Fuller J, Graefe T, Kaatz M, Lopatta E. Angiosarcoma of the scalp :treatment with liposomal doxorubicin and radiotherapy. *J Cancer Res Clin Oncol* 2001 ; 127(6) :396-9.
13. Merimsky O, Meller I, Flusser G et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy : a phase II study. *Cancer Chemother Pharmacol* 2000 ;45(2) :177-81.
14. Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. *Cancer* 1999 Nov 15 ;86(10) :2034-7.
15. Casper ES, Waltzman RJ, Scharf GK et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. *Cancer Invest* 1998 ; 16(7) :442-6.
16. Morimura Y, Hashimoto T, Soeda S et al. Angiosarcoma of vagina successfully treated with interleukin-2 therapy and chemotherapy : a case report. *J Obstet Gynaecol Res* 2001 Aug ;27(4): 231-5.
17. Kiyosawa T, Demitsu T, Murashita T et al. Eradication of metastatic angiosarcoma of the lower extremity. *Scand J Plast Reconstr Surg Hand Surg* 2000 Sep ;34(3) :269-71.
18. Guillot B, Raison-Peyron N, Acevedo M et al. Angiosarcoma of the scalp and face : failure of an interferon

alpha treatment. Eur J Dermatol 2000 Jun ;10(4) :300-2.
19. Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF.

Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 1996 Jun 1 ;77(11) :2400-6.

Author Information

José L.M. Guimarães

Department of Clinical Oncology, Grupo Hospitalar Conceição

Sören Franz Marian Chicata Sutmöller

Santa Casa de Misericórdia

Max S. Mano

Department of Chemotherapy, Institut Jules Bordet

Christian Sandor Svend Chicata Sutmöller

Department of Clinical Oncology, Grupo Hospitalar Conceição

Roberta Venturella

Department of Clinical Oncology, Grupo Hospitalar Conceição

Fábio Franke

Department of Clinical Oncology, Grupo Hospitalar Conceição

Andre Reiriz

Department of Clinical Oncology, Grupo Hospitalar Conceição

Alessandra Notari

Santa Casa de Misericórdia

Angelo Di Leo

Department of Chemotherapy, Institut Jules Bordet